Serono Rebif 25% Market Share Expected By 2006; Monthly Price Is $1,156
Executive Summary
Serono hopes Rebif will capture a quarter of the multiple sclerosis market by 2006, CEO Ernesto Bertarelli told securities analysts during a March 11 conference call
You may also be interested in...
Biogen Idec Addressing Avonex Liquid Formulation Manufacturing Problems
Biogen Idec is working to address Avonex fill-finish manufacturing problems with the recently approved liquid formulation of the multiple sclerosis therapy
Biogen Idec Addressing Avonex Liquid Formulation Manufacturing Problems
Biogen Idec is working to address Avonex fill-finish manufacturing problems with the recently approved liquid formulation of the multiple sclerosis therapy
Biogen Amevive Revival Strategy Includes Shorter Time To Reimbursement
Biogen's strategy to meet its Amevive (alefacept) 2003 sales target includes increasing the physician referral rate and shortening the time needed for patients to secure reimbursement